Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-Year follow-up from a randomized phase 3 trial (DASISION)

Hagop M. Kantarjian, Neil P. Shah, Jorge E. Cortes, Michele Baccarani, Mohan B. Agarwal, María Soledad Undurraga, Jianxiang Wang, Juan Julio Kassack Ipiña, Dong Wook Kim, Michinori Ogura, Carolina Pavlovsky, Christian Junghanss, Jorge H. Milone, Franck E. Nicolini, Tadeusz Robak, Jan Van Droogenbroeck, Edo Vellenga, M. Brigid Bradley-Garelik, Chao Zhu, Andreas Hochhaus

Research output: Contribution to journalArticlepeer-review

443 Scopus citations

Fingerprint

Dive into the research topics of 'Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-Year follow-up from a randomized phase 3 trial (DASISION)'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemical Compounds